Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10823093,peripheral volume of distribution,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw],612,381,DB01236,Sevoflurane
,10823093,peripheral volume of distribution,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw],4112,382,DB01236,Sevoflurane
,10823093,peripheral volume of distribution,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw],1634,383,DB01236,Sevoflurane
,10823093,transport clearance from,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw·min],7.0,384,DB01236,Sevoflurane
,10823093,transport clearance from,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw·min],30.7,385,DB01236,Sevoflurane
,10823093,transport clearance from,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw·min],13.0,386,DB01236,Sevoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.35,2177,DB01236,Sevoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.45,2178,DB01236,Sevoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.94,2179,DB01236,Sevoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,2.54,2180,DB01236,Sevoflurane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,93,2181,DB01236,Sevoflurane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,77,2182,DB01236,Sevoflurane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,111,2183,DB01236,Sevoflurane
<,25061702,plasma concentrations,"During the fentanyl CRI, mean ± SD plasma fentanyl concentration decreased from 4.41 ± 1.86 ng/mL to 2.99 ± 1.28 ng/mL and was correlated with antinociception; plasma concentrations < 1.33 ± 0.30 ng/mL were not associated with antinociception.",Pharmacokinetics and pharmacodynamics of a constant rate infusion of fentanyl (5 μg/kg/h) in awake cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061702/),ng,1.33,7182,DB01236,Sevoflurane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB01236,Sevoflurane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB01236,Sevoflurane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB01236,Sevoflurane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB01236,Sevoflurane
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB01236,Sevoflurane
,29494403,time to 80% block,"The time to 80% block was predicted to be 1.5, 0.8, and 0.7 min for 2×, 3×, and 4× ED95 doses, respectively.","Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494403/),min,1.5,9146,DB01236,Sevoflurane
,29494403,time to 80% block,"The time to 80% block was predicted to be 1.5, 0.8, and 0.7 min for 2×, 3×, and 4× ED95 doses, respectively.","Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494403/),min,0.8,9147,DB01236,Sevoflurane
,29494403,time to 80% block,"The time to 80% block was predicted to be 1.5, 0.8, and 0.7 min for 2×, 3×, and 4× ED95 doses, respectively.","Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494403/),min,0.7,9148,DB01236,Sevoflurane
,29562829,half-life,"The mean half-life and mean residence time of alfaxalone were longer after I/M (1.28 (SD 0.21) and 2.09 (SD 0.36) hours, respectively) than after I/V (0.49 (SD 0.07) and 0.66 (SD 0.16) hours, respectively) administration (p<0.05).",Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29562829/),h,1.28,12862,DB01236,Sevoflurane
,29562829,half-life,"The mean half-life and mean residence time of alfaxalone were longer after I/M (1.28 (SD 0.21) and 2.09 (SD 0.36) hours, respectively) than after I/V (0.49 (SD 0.07) and 0.66 (SD 0.16) hours, respectively) administration (p<0.05).",Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29562829/),h,0.49,12863,DB01236,Sevoflurane
,29562829,mean residence time,"The mean half-life and mean residence time of alfaxalone were longer after I/M (1.28 (SD 0.21) and 2.09 (SD 0.36) hours, respectively) than after I/V (0.49 (SD 0.07) and 0.66 (SD 0.16) hours, respectively) administration (p<0.05).",Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29562829/),h,2.09,12864,DB01236,Sevoflurane
,29562829,mean residence time,"The mean half-life and mean residence time of alfaxalone were longer after I/M (1.28 (SD 0.21) and 2.09 (SD 0.36) hours, respectively) than after I/V (0.49 (SD 0.07) and 0.66 (SD 0.16) hours, respectively) administration (p<0.05).",Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29562829/),h,0.66,12865,DB01236,Sevoflurane
,29562829,Bioavailability,Bioavailability after I/M injection of alfaxalone was 94.7 (SD 19.8)%.,Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29562829/),%,94.7,12866,DB01236,Sevoflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],39.8,32819,DB01236,Sevoflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],28.3,32820,DB01236,Sevoflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],32.6,32821,DB01236,Sevoflurane
,9350366,half-life,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),min,14,32822,DB01236,Sevoflurane
,9350366,clearance,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[l] / [min],2.1,32823,DB01236,Sevoflurane
,24226486,plasma concentration,The mean plasma concentration of sevoflurane was 76 mg/L at 24 h and 70 mg/L at 48 h.,A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),[mg] / [l],76,35274,DB01236,Sevoflurane
,24226486,plasma concentration,The mean plasma concentration of sevoflurane was 76 mg/L at 24 h and 70 mg/L at 48 h.,A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),[mg] / [l],70,35275,DB01236,Sevoflurane
,24226486,free plasma fraction,The mean free plasma fraction of hexafluoroisopropanol never exceeded 8 mg/mL.,A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),[mg] / [ml],8,35276,DB01236,Sevoflurane
,24226486,distribution volume,"The distribution volume was 53 L, the elimination constant 2.9 h-1, the transfer constant from compartment 1 to compartment 2 (K1-2) 1.2 h-1, the K2-1 0.26 h-1, the half-life of elimination 3.78 h, and the total clearance 156 L/h.",A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),l,53,35277,DB01236,Sevoflurane
,24226486,elimination constant,"The distribution volume was 53 L, the elimination constant 2.9 h-1, the transfer constant from compartment 1 to compartment 2 (K1-2) 1.2 h-1, the K2-1 0.26 h-1, the half-life of elimination 3.78 h, and the total clearance 156 L/h.",A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),1/[h],2.9,35278,DB01236,Sevoflurane
,24226486,transfer constant from compartment 1 to compartment 2 (K1-2),"The distribution volume was 53 L, the elimination constant 2.9 h-1, the transfer constant from compartment 1 to compartment 2 (K1-2) 1.2 h-1, the K2-1 0.26 h-1, the half-life of elimination 3.78 h, and the total clearance 156 L/h.",A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),1/[h],1.2,35279,DB01236,Sevoflurane
,24226486,K2-1,"The distribution volume was 53 L, the elimination constant 2.9 h-1, the transfer constant from compartment 1 to compartment 2 (K1-2) 1.2 h-1, the K2-1 0.26 h-1, the half-life of elimination 3.78 h, and the total clearance 156 L/h.",A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),1/[h],0.26,35280,DB01236,Sevoflurane
,24226486,half-life of elimination,"The distribution volume was 53 L, the elimination constant 2.9 h-1, the transfer constant from compartment 1 to compartment 2 (K1-2) 1.2 h-1, the K2-1 0.26 h-1, the half-life of elimination 3.78 h, and the total clearance 156 L/h.",A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),h,3.78,35281,DB01236,Sevoflurane
,24226486,total clearance,"The distribution volume was 53 L, the elimination constant 2.9 h-1, the transfer constant from compartment 1 to compartment 2 (K1-2) 1.2 h-1, the K2-1 0.26 h-1, the half-life of elimination 3.78 h, and the total clearance 156 L/h.",A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24226486/),[l] / [h],156,35282,DB01236,Sevoflurane
,20876699,T₄/T₁ ratio,The primary efficacy variable was time from the start of sugammadex administration to recovery of T₄/T₁ ratio to 0.9.,Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),,0.9,40194,DB01236,Sevoflurane
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,0.9,40195,DB01236,Sevoflurane
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,96.3,40196,DB01236,Sevoflurane
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,1.5,40197,DB01236,Sevoflurane
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,79.0,40198,DB01236,Sevoflurane
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,3.0,40199,DB01236,Sevoflurane
,22242687,Areas under the curve,"Areas under the curve for anandamide (mean and 95% CI) were 53.3 (47.4, 59.2) nmol l(-1) 60 min with propofol and 48.5 (43.1, 53.8) nmol l(-1) 60 min with thiopental/sevoflurane (P= NS).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [l],53.3,45543,DB01236,Sevoflurane
,22242687,Areas under the curve,"Areas under the curve for anandamide (mean and 95% CI) were 53.3 (47.4, 59.2) nmol l(-1) 60 min with propofol and 48.5 (43.1, 53.8) nmol l(-1) 60 min with thiopental/sevoflurane (P= NS).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [l],48.5,45544,DB01236,Sevoflurane
,22242687,K(m),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[μM] / [l],16.9,45545,DB01236,Sevoflurane
,22242687,V(max),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [mg·min],44.6,45546,DB01236,Sevoflurane
,22242687,K(m),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[μM] / [l],16.6,45547,DB01236,Sevoflurane
,22242687,V(max),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[1·mg·nM] / [min],44.0,45548,DB01236,Sevoflurane
,19558370,MAC,The MAC of Sevo was 2.30 +/- 0.19%.,Effect of lidocaine on the minimum alveolar concentration of sevoflurane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558370/),%,2.30,47868,DB01236,Sevoflurane
,19558370,plasma concentration,Lidocaine plasma concentration was 0.84 +/- 0.18 for LCRI and 1.89 +/- 0.37 microg mL(-1) for HCRI.,Effect of lidocaine on the minimum alveolar concentration of sevoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558370/),[μg] / [ml],0.84,47869,DB01236,Sevoflurane
,19558370,plasma concentration,Lidocaine plasma concentration was 0.84 +/- 0.18 for LCRI and 1.89 +/- 0.37 microg mL(-1) for HCRI.,Effect of lidocaine on the minimum alveolar concentration of sevoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558370/),[μg] / [ml],1.89,47870,DB01236,Sevoflurane
,12402722,peak plasma concentration,"The peak plasma concentration achieved was significantly higher in the bupivacaine group compared with the ropivacaine group (2.2 vs 1.2 micrograms ml-1, P = 0.025).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),[μg] / [ml],2.2,49115,DB01236,Sevoflurane
,12402722,peak plasma concentration,"The peak plasma concentration achieved was significantly higher in the bupivacaine group compared with the ropivacaine group (2.2 vs 1.2 micrograms ml-1, P = 0.025).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),[μg] / [ml],1.2,49116,DB01236,Sevoflurane
,12402722,time to peak plasma concentration,"The time to peak plasma concentration was significantly shorter in the bupivacaine group (24 vs 35 min, P = 0.024).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,24,49117,DB01236,Sevoflurane
,12402722,time to peak plasma concentration,"The time to peak plasma concentration was significantly shorter in the bupivacaine group (24 vs 35 min, P = 0.024).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,35,49118,DB01236,Sevoflurane
,12402722,initial distribution half time,"The initial distribution half time of bupivacaine was significantly shorter (3.6 vs 6.5 min, P = 0.020) compared with that of ropivacaine.",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,3.6,49119,DB01236,Sevoflurane
,12402722,initial distribution half time,"The initial distribution half time of bupivacaine was significantly shorter (3.6 vs 6.5 min, P = 0.020) compared with that of ropivacaine.",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,6.5,49120,DB01236,Sevoflurane
,30078791,Maximum serum concentration of robenacoxib (Cmax),Maximum serum concentration of robenacoxib (Cmax) was 2.2 µg/ml [range: 1.2-4.6] (median [range: minimum-maximum]) and time of Cmax (Tmax) was 90 min [range: 60-120] in the conscious dogs.,Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078791/),[μg] / [ml],2.2,61650,DB01236,Sevoflurane
,30078791,time of Cmax (Tmax),Maximum serum concentration of robenacoxib (Cmax) was 2.2 µg/ml [range: 1.2-4.6] (median [range: minimum-maximum]) and time of Cmax (Tmax) was 90 min [range: 60-120] in the conscious dogs.,Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078791/),min,90,61651,DB01236,Sevoflurane
,30078791,Cmax,"In the sevoflurane-anesthetized dogs, the Cmax significantly declined (1.3 µg/ml [range: 0.8-1.4], P=0.008) and Tmax was delayed (120 min [range: 120-240], P=0.018) compared with those in the conscious dogs.",Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078791/),[μg] / [ml],1.3,61652,DB01236,Sevoflurane
,30078791,Tmax,"In the sevoflurane-anesthetized dogs, the Cmax significantly declined (1.3 µg/ml [range: 0.8-1.4], P=0.008) and Tmax was delayed (120 min [range: 120-240], P=0.018) compared with those in the conscious dogs.",Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078791/),min,120,61653,DB01236,Sevoflurane
,30078791,serum robenacoxib concentration at 240 min (C240),"The serum robenacoxib concentration at 240 min (C240) decreased to 0.5 µg/ml [range: 0.2-0.9] in the conscious dogs, while it remained higher in the sevoflurane-anesthetized dogs (1.0 µg/ml [range: 0.3-1.4], P=0.011).",Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078791/),[μg] / [ml],0.5,61654,DB01236,Sevoflurane
,30078791,serum robenacoxib concentration at 240 min (C240),"The serum robenacoxib concentration at 240 min (C240) decreased to 0.5 µg/ml [range: 0.2-0.9] in the conscious dogs, while it remained higher in the sevoflurane-anesthetized dogs (1.0 µg/ml [range: 0.3-1.4], P=0.011).",Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078791/),[μg] / [ml],1.0,61655,DB01236,Sevoflurane
,23824662,peak sugammadex concentration,"The mean peak sugammadex concentration was 66.5 μg/mL, with exposure similar in the sevoflurane/propofol groups.",Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23824662/),[μg] / [ml],66.5,65938,DB01236,Sevoflurane
,33386432,time to reach maximum plasma concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),min,2,73226,DB01236,Sevoflurane
,33386432,time to reach maximum plasma concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),min,5,73227,DB01236,Sevoflurane
,33386432,maximum concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[μg] / [ml],0.45,73228,DB01236,Sevoflurane
,33386432,maximum concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[μg] / [ml],0.47,73229,DB01236,Sevoflurane
,33386432,area under the curve from time 0 to 120 min,The area under the curve from time 0 to 120 min after levobupivacaine administration was significantly higher in the SC group than in the IP group in both experiments (IP: 0.29 [0.10-0.54] mg h/L; SC: 0.78 [0.39-0.98] mg h/L; P = 0.04).,Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[h·mg] / [l],0.29,73230,DB01236,Sevoflurane
,33386432,area under the curve from time 0 to 120 min,The area under the curve from time 0 to 120 min after levobupivacaine administration was significantly higher in the SC group than in the IP group in both experiments (IP: 0.29 [0.10-0.54] mg h/L; SC: 0.78 [0.39-0.98] mg h/L; P = 0.04).,Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[h·mg] / [l],0.78,73231,DB01236,Sevoflurane
exceed,33386432,Tmax,"On the other hand, when levobupivacaine is given subcutaneously, Tmax can exceed 1 h, so we need to be aware of local anesthetic toxicity during this period.",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),h,1,73232,DB01236,Sevoflurane
,17006727,BIS,General anesthesia was administered to 15 ASA I-II patients with a continuous infusion of propofol to maintain a BIS value of 45 +/- 5.,"The influence of sevoflurane on the bispectral index, regional cerebral oxygen saturation, and propofol concentration during propofol/N2O anesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006727/),,45,79653,DB01236,Sevoflurane
,17006727,concentration,"Propofol concentration was increased from 2.71 +/- 0.51 microg/ml to 3.30 +/- 0.57 microg/ml (P < 0.05) after sevoflurane application, and was returned to baseline after sevoflurane washout.","The influence of sevoflurane on the bispectral index, regional cerebral oxygen saturation, and propofol concentration during propofol/N2O anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006727/),[μg] / [ml],2.71,79654,DB01236,Sevoflurane
,17006727,concentration,"Propofol concentration was increased from 2.71 +/- 0.51 microg/ml to 3.30 +/- 0.57 microg/ml (P < 0.05) after sevoflurane application, and was returned to baseline after sevoflurane washout.","The influence of sevoflurane on the bispectral index, regional cerebral oxygen saturation, and propofol concentration during propofol/N2O anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006727/),[μg] / [ml],3.30,79655,DB01236,Sevoflurane
,9706952,gas flow,Ten patients (aged 40-70 yr) who had received sevoflurane anesthesia with a gas flow of 6 L/min for neurosurgery twice in 30-90 days were studied.,Inorganic fluoride kinetics and renal and hepatic function after repeated sevoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706952/),[l] / [min],6,80280,DB01236,Sevoflurane
,9989340,blood/gas partition coefficient,The more rapid pharmacokinetics are a result of the low blood/gas partition coefficient of 0.69.,Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),,0.69,82479,DB01236,Sevoflurane
,9989340,oil/gas partition coefficient,"With an oil/gas partition coefficient of 47.2, the minimum alveolar concentration (MAC) of sevoflurane is 2.05%.",Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),,47.2,82480,DB01236,Sevoflurane
,9989340,minimum alveolar concentration (MAC),"With an oil/gas partition coefficient of 47.2, the minimum alveolar concentration (MAC) of sevoflurane is 2.05%.",Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),%,2.05,82481,DB01236,Sevoflurane
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.0,82912,DB01236,Sevoflurane
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.47,82913,DB01236,Sevoflurane
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.70,82914,DB01236,Sevoflurane
,18806024,plasma concentrations,"The mean remifentanil plasma concentrations (+/-sd) at 2, 3, 4, and 10 min were 1.0 (0.60), 1.47 (0.52), 1.70 (0.46), and 1.16 (0.36) ng/mL, respectively.",The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806024/),[ng] / [ml],1.16,82915,DB01236,Sevoflurane
,1731542,total gas flow,"Sevoflurane or isoflurane was administered with a semiclosed (total gas flow, 2 L/min O2) circle absorption system for durations of 1.0 to greater than 7.0 minimal alveolar concentration (MAC) hours for surgical anesthesia (sevoflurane MAC, 2.05%; isoflurane MAC, 1.15%).",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[l] / [min·o2],2,95779,DB01236,Sevoflurane
,1731542,peak plasma inorganic fluoride concentration,"Sevoflurane biotransformation produced a mean peak plasma inorganic fluoride concentration of 29.3 +/- 1.8 mumol/L, 2 h after anesthesia, which decreased to 18 mumol/L concentration by 8 h after anesthesia.",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[μM] / [l],29.3,95780,DB01236,Sevoflurane
,1731542,peak plasma inorganic fluoride concentration,"Sevoflurane biotransformation produced a mean peak plasma inorganic fluoride concentration of 29.3 +/- 1.8 mumol/L, 2 h after anesthesia, which decreased to 18 mumol/L concentration by 8 h after anesthesia.",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[μM] / [l],18,95781,DB01236,Sevoflurane
exceeding,1731542,peak levels,"Five patients given sevoflurane had peak levels transiently exceeding 50 mumol/L, and one of these had a history of ingesting drugs potentially producing hepatic enzyme induction.",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[μM] / [l],50,95782,DB01236,Sevoflurane
,18806025,Cmax,Median (range) levobupivacaine Cmax and Tmax measured were 1.48 (0.62-2.40) microg/mL and 37 (10-60) min.,Pharmacokinetics of levobupivacaine (2.5 mg/kg) after caudal administration in children younger than 3 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806025/),[μg] / [ml],1.48,106980,DB01236,Sevoflurane
,18806025,Tmax,Median (range) levobupivacaine Cmax and Tmax measured were 1.48 (0.62-2.40) microg/mL and 37 (10-60) min.,Pharmacokinetics of levobupivacaine (2.5 mg/kg) after caudal administration in children younger than 3 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806025/),min,37,106981,DB01236,Sevoflurane
,15681947,renal extraction ratio,The renal extraction ratio of propofol was 0.58 +/- 0.15 (mean +/- SD).,Human kidneys play an important role in the elimination of propofol. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),,0.58,112897,DB01236,Sevoflurane
,15681947,renal clearance,"The renal clearance of propofol was 0.41 +/- 0.15 l/min (mean +/- SD), or 27 +/- 9.9% (mean +/- SD) of total body clearance.",Human kidneys play an important role in the elimination of propofol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),[l] / [min],0.41,112898,DB01236,Sevoflurane
,15681947,renal clearance,"The renal clearance of propofol was 0.41 +/- 0.15 l/min (mean +/- SD), or 27 +/- 9.9% (mean +/- SD) of total body clearance.",Human kidneys play an important role in the elimination of propofol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),%,27,112899,DB01236,Sevoflurane
,31837511,MAC-BARsevo,"Mean MAC-BARsevo of the ketamine and placebo were 2.73 ± 0.23% and 2.77 ± 0.31%, respectively and no significant difference was found (p = .638).",Determination of the minimum alveolar concentration of sevoflurane that blunts adrenergic responses and the effect of a constant rate infusion of ketamine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31837511/),%,2.73,129803,DB01236,Sevoflurane
,31837511,MAC-BARsevo,"Mean MAC-BARsevo of the ketamine and placebo were 2.73 ± 0.23% and 2.77 ± 0.31%, respectively and no significant difference was found (p = .638).",Determination of the minimum alveolar concentration of sevoflurane that blunts adrenergic responses and the effect of a constant rate infusion of ketamine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31837511/),%,2.77,129804,DB01236,Sevoflurane
,31837511,plasma concentrations,Average ketamine plasma concentrations was 1.54 ± 0.18 μg/mL maintained through the study.,Determination of the minimum alveolar concentration of sevoflurane that blunts adrenergic responses and the effect of a constant rate infusion of ketamine in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31837511/),[μg] / [ml],1.54,129805,DB01236,Sevoflurane
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,6.34,133161,DB01236,Sevoflurane
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,1.85,133162,DB01236,Sevoflurane
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,1.10,133163,DB01236,Sevoflurane
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,8.16,133164,DB01236,Sevoflurane
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,9.47,133165,DB01236,Sevoflurane
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,10.0,133166,DB01236,Sevoflurane
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.0,133167,DB01236,Sevoflurane
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.4,133168,DB01236,Sevoflurane
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.6,133169,DB01236,Sevoflurane
,12779111,duration of,The mean duration of anesthesia was 27.9 +/- 10.1 minutes.,Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),min,27.9,136685,DB01236,Sevoflurane
,12779111,elimination half-life,"The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg.",Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),h,3.6,136686,DB01236,Sevoflurane
,12779111,serum clearance,"The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg.",Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),[ml] / [kg·min],5.6,136687,DB01236,Sevoflurane
,12779111,volume of distribution,"The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg.",Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),[l] / [kg],4.1,136688,DB01236,Sevoflurane
,12779111,elimination half-life,The M1 elimination half-life was 5.8 +/- 1.7 hours.,Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),h,5.8,136689,DB01236,Sevoflurane
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147638,DB01236,Sevoflurane
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147639,DB01236,Sevoflurane
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147640,DB01236,Sevoflurane
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147641,DB01236,Sevoflurane
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147642,DB01236,Sevoflurane
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147643,DB01236,Sevoflurane
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147644,DB01236,Sevoflurane
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147645,DB01236,Sevoflurane
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,168",147646,DB01236,Sevoflurane
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147647,DB01236,Sevoflurane
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147648,DB01236,Sevoflurane
,14564578,half-lives of the central,"The half-lives of the central and peripheral compartment ( t(1/2)alpha and t(1/2)beta) were 2.26 +/- 0.69 and 47.9 +/- 22.1 min, respectively.",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),min,2.26,149532,DB01236,Sevoflurane
,14564578,t(1/2)beta,"The half-lives of the central and peripheral compartment ( t(1/2)alpha and t(1/2)beta) were 2.26 +/- 0.69 and 47.9 +/- 22.1 min, respectively.",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),min,47.9,149533,DB01236,Sevoflurane
,14564578,volume of the central compartment (V(c)),"The volume of the central compartment (V(c)) was 0.582 +/- 0.170 l.kg(-1), and the apparent volume of distribution at a steady state (V(dss)) was 2.62 +/- 1.06 l.kg(-1).",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),[l] / [kg],0.582,149534,DB01236,Sevoflurane
,14564578,apparent volume of distribution at a steady state (V(dss)),"The volume of the central compartment (V(c)) was 0.582 +/- 0.170 l.kg(-1), and the apparent volume of distribution at a steady state (V(dss)) was 2.62 +/- 1.06 l.kg(-1).",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),[l] / [kg],2.62,149535,DB01236,Sevoflurane
,14564578,total body clearance (Cl),The total body clearance (Cl) and mean residence time (MRT) were 53.7 +/- 11.9 ml.min(-1).,Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),[ml] / [min],53.7,149536,DB01236,Sevoflurane
,21535448,reversal times,"Simulated reversal times in typical adults were 0.8, 1.5 and 1.4 min upon reversal with sugammadex 16 mg kg(-1) 3 min after rocuronium, sugammadex 4 mg kg(-1) during deep neuromuscular blockade and sugammadex 2 mg kg(-1) during moderate blockade, respectively.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,0.8,165601,DB01236,Sevoflurane
,21535448,reversal times,"Simulated reversal times in typical adults were 0.8, 1.5 and 1.4 min upon reversal with sugammadex 16 mg kg(-1) 3 min after rocuronium, sugammadex 4 mg kg(-1) during deep neuromuscular blockade and sugammadex 2 mg kg(-1) during moderate blockade, respectively.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,1.5,165602,DB01236,Sevoflurane
,21535448,reversal times,"Simulated reversal times in typical adults were 0.8, 1.5 and 1.4 min upon reversal with sugammadex 16 mg kg(-1) 3 min after rocuronium, sugammadex 4 mg kg(-1) during deep neuromuscular blockade and sugammadex 2 mg kg(-1) during moderate blockade, respectively.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,1.4,165603,DB01236,Sevoflurane
<,21535448,reversal time,"Simulations of the therapeutic dosing regimens demonstrated limited impact of age, renal function and sevoflurane use, as predicted reversal time in typical subjects was always <2 min.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,2,165604,DB01236,Sevoflurane
,15675927,tolerated dose,The median tolerated dose of remifentanil was 0.127 microg.kg(-1).min(-1) (range: 0.053-0.3 microg.kg(-1).min(-1)).,Spontaneous ventilation with remifentanil in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15675927/),[μg] / [kg·min],0.127,169192,DB01236,Sevoflurane
<,15675927,respiratory rate,A respiratory rate of <10 b.min(-1) appears to be the best predictor of the maximum tolerated dose.,Spontaneous ventilation with remifentanil in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15675927/),[b] / [min],10,169193,DB01236,Sevoflurane
,29455032,expired fraction,The sevoflurane was administered with an expired fraction target of 2% during short-term procedural sedation.,Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),%,2,170703,DB01236,Sevoflurane
,29455032,total burn surface area,The mean total burn surface area was 36±11%.,Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),%,36,170704,DB01236,Sevoflurane
,29455032,plasma concentration,The average plasma concentration of sevoflurane was 70.4±37.5mg·L-1 in burns and 57.2±28.1mg·L-1 in controls at the end of the procedure (P=0.58).,Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),[mg] / [l],70.4,170705,DB01236,Sevoflurane
,29455032,plasma concentration,The average plasma concentration of sevoflurane was 70.4±37.5mg·L-1 in burns and 57.2±28.1mg·L-1 in controls at the end of the procedure (P=0.58).,Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),[mg] / [l],57.2,170706,DB01236,Sevoflurane
,29455032,volume of distribution,"The volume of distribution was higher (46.8±7.2 vs 22.2±2.50L, P<0.001), and the drug half-life longer in burns (1.19±0.28h vs 0.65±0.04h, P<0.0001).",Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),l,46.8,170707,DB01236,Sevoflurane
,29455032,volume of distribution,"The volume of distribution was higher (46.8±7.2 vs 22.2±2.50L, P<0.001), and the drug half-life longer in burns (1.19±0.28h vs 0.65±0.04h, P<0.0001).",Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),l,22.2,170708,DB01236,Sevoflurane
,29455032,half-life,"The volume of distribution was higher (46.8±7.2 vs 22.2±2.50L, P<0.001), and the drug half-life longer in burns (1.19±0.28h vs 0.65±0.04h, P<0.0001).",Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),h,1.19,170709,DB01236,Sevoflurane
,29455032,half-life,"The volume of distribution was higher (46.8±7.2 vs 22.2±2.50L, P<0.001), and the drug half-life longer in burns (1.19±0.28h vs 0.65±0.04h, P<0.0001).",Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29455032/),h,0.65,170710,DB01236,Sevoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,6,171264,DB01236,Sevoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,2,171265,DB01236,Sevoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.15,171266,DB01236,Sevoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.7,171267,DB01236,Sevoflurane
,11038831,fractional end tidal alveolar concentration (Fa),The fractional end tidal alveolar concentration (Fa) was adjusted to 1MAC during the maintenance of anesthsia.,"[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),,1,171268,DB01236,Sevoflurane
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],117,175692,DB01236,Sevoflurane
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],286,175693,DB01236,Sevoflurane
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],705,175694,DB01236,Sevoflurane
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],53,175695,DB01236,Sevoflurane
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],334,175696,DB01236,Sevoflurane
,31983556,clearance,"Midazolam clearance to 1-hydroxymidazolam, midazolam fast and slow intercompartmental clearances, 1-hydroxymidazolam clearance and 1-hydroxymidazolam intercompartment clearance were 18.3, 63.5 (15), 22.1 (8), 1.7 (67) and 3.8 mL minute-1 kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg·min],18.3,175697,DB01236,Sevoflurane
,31983556,intercompartment clearance,"Midazolam clearance to 1-hydroxymidazolam, midazolam fast and slow intercompartmental clearances, 1-hydroxymidazolam clearance and 1-hydroxymidazolam intercompartment clearance were 18.3, 63.5 (15), 22.1 (8), 1.7 (67) and 3.8 mL minute-1 kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg·min],1.7,175698,DB01236,Sevoflurane
,31983556,intercompartment clearance,"Midazolam clearance to 1-hydroxymidazolam, midazolam fast and slow intercompartmental clearances, 1-hydroxymidazolam clearance and 1-hydroxymidazolam intercompartment clearance were 18.3, 63.5 (15), 22.1 (8), 1.7 (67) and 3.8 mL minute-1 kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg·min],3.8,175699,DB01236,Sevoflurane
,28283250,bispectral index,The bispectral index was maintained between 40 and 60 during cardiopulmonary bypass.,Feasibility of Anesthesia Maintenance With Sevoflurane During Cardiopulmonary Bypass: A Pilot Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283250/),,40 and 60,180105,DB01236,Sevoflurane
,28283250,plasma concentration,"However, the sevoflurane plasma concentration was not significantly different before and after cardiopulmonary bypass start-up (40.55 µg/mL [76.62-125.33] before cardiopulmonary bypass and 36.24 µg/mL [56.49-81-42] during cardiopulmonary bypass).",Feasibility of Anesthesia Maintenance With Sevoflurane During Cardiopulmonary Bypass: A Pilot Pharmacokinetics Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283250/),[μg] / [ml],40.55,180106,DB01236,Sevoflurane
,28283250,plasma concentration,"However, the sevoflurane plasma concentration was not significantly different before and after cardiopulmonary bypass start-up (40.55 µg/mL [76.62-125.33] before cardiopulmonary bypass and 36.24 µg/mL [56.49-81-42] during cardiopulmonary bypass).",Feasibility of Anesthesia Maintenance With Sevoflurane During Cardiopulmonary Bypass: A Pilot Pharmacokinetics Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283250/),[μg] / [ml],36.24,180107,DB01236,Sevoflurane
,24982551,plasma concentrations,Mean fentanyl plasma concentrations did not differ (P ≥ 0.05) between T1 (3.70 ± 0.56 ng/mL) and T3 (3.50 ± 0.56 ng/mL).,The interaction of nitrous oxide and fentanyl on the minimum alveolar concentration of sevoflurane blocking motor movement (MACNM) in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24982551/),[ng] / [ml],3.70,197770,DB01236,Sevoflurane
,24982551,plasma concentrations,Mean fentanyl plasma concentrations did not differ (P ≥ 0.05) between T1 (3.70 ± 0.56 ng/mL) and T3 (3.50 ± 0.56 ng/mL).,The interaction of nitrous oxide and fentanyl on the minimum alveolar concentration of sevoflurane blocking motor movement (MACNM) in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24982551/),[ng] / [ml],3.50,197771,DB01236,Sevoflurane
,19948429,LOD,"LOD and LOQ are 0.2 and 1microg/ml, with a short analysis time (7.6 min for a single analysis).",Simple assay of plasma sevoflurane and its metabolite hexafluoroisopropanol by headspace GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948429/),[μg] / [ml],0.2,198592,DB01236,Sevoflurane
,19948429,LOQ,"LOD and LOQ are 0.2 and 1microg/ml, with a short analysis time (7.6 min for a single analysis).",Simple assay of plasma sevoflurane and its metabolite hexafluoroisopropanol by headspace GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948429/),[μg] / [ml],1,198593,DB01236,Sevoflurane
,8094451,excretion half-life,The excretion half-life for the metabolite was calculated to be 55 h.,Urinary excretion of hexafluoroisopropanol glucuronide and fluoride in patients after sevoflurane anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094451/),h,55,199701,DB01236,Sevoflurane
,8094451,excretion,"The cumulative organic and inorganic fluoride excretion in the 3 days after sevoflurane anaesthesia was 1588 and 856 mumol, respectively (ratio = 1.85).",Urinary excretion of hexafluoroisopropanol glucuronide and fluoride in patients after sevoflurane anaesthesia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094451/),μM,1588,199702,DB01236,Sevoflurane
,8094451,excretion,"The cumulative organic and inorganic fluoride excretion in the 3 days after sevoflurane anaesthesia was 1588 and 856 mumol, respectively (ratio = 1.85).",Urinary excretion of hexafluoroisopropanol glucuronide and fluoride in patients after sevoflurane anaesthesia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094451/),μM,856,199703,DB01236,Sevoflurane
,8094451,excreted half-lives,"The excreted half-lives for organic and inorganic fluoride were calculated to be 4028 and 2069 min, respectively.",Urinary excretion of hexafluoroisopropanol glucuronide and fluoride in patients after sevoflurane anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094451/),min,4028,199704,DB01236,Sevoflurane
,8094451,excreted half-lives,"The excreted half-lives for organic and inorganic fluoride were calculated to be 4028 and 2069 min, respectively.",Urinary excretion of hexafluoroisopropanol glucuronide and fluoride in patients after sevoflurane anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094451/),min,2069,199705,DB01236,Sevoflurane
,25697421,MAC,"The mean MAC was similar for generic and original sevoflurane (median [range], 0.93 [0.67-1.29] vs 0.94 [0.63-1.5] vol%).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),vol%,0.93,206295,DB01236,Sevoflurane
,25697421,MAC,"The mean MAC was similar for generic and original sevoflurane (median [range], 0.93 [0.67-1.29] vs 0.94 [0.63-1.5] vol%).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),vol%,0.94,206296,DB01236,Sevoflurane
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),[h·μM] / [l],333.7,206297,DB01236,Sevoflurane
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),[h·μM] / [l],311.9,206298,DB01236,Sevoflurane
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),h·ppm,51.8,206299,DB01236,Sevoflurane
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),h·ppm,55.3,206300,DB01236,Sevoflurane
,32880998,V1,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),l,1.14,212524,DB01236,Sevoflurane
,32880998,V2,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),l,77.6,212525,DB01236,Sevoflurane
,32880998,CL1,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),[l] / [min],0.00182,212526,DB01236,Sevoflurane
,32880998,CL2,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),[l] / [min],0.0461,212527,DB01236,Sevoflurane
,7793651,Apparent renal fluoride,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),[ml] / [min],51.8,216581,DB01236,Sevoflurane
,7793651,clearances,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),[ml] / [min],52.6,216582,DB01236,Sevoflurane
,7793651,apparent elimination half-lives,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),h,21.4,216583,DB01236,Sevoflurane
,7793651,apparent elimination half-lives,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),h,20.1,216584,DB01236,Sevoflurane
,7793651,Renal,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"4,300",216585,DB01236,Sevoflurane
,7793651,HFIP,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"4,300",216586,DB01236,Sevoflurane
,7793651,net fluoride excretion,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"3,300",216587,DB01236,Sevoflurane
,17580185,total gas flow,"Anesthesia was maintained with sevoflurane (2%), O(2), and N(2)O at a total gas flow of 6 L . min(-1) using a semiclosed circle system with a sodalime canister.",Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),[l] / [min],6,221315,DB01236,Sevoflurane
,17580185,duration of surgery,Mean duration of surgery was 9:06 +/- 0:09 hours.,Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),h,9:06,221316,DB01236,Sevoflurane
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.42,227640,DB01236,Sevoflurane
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.40,227641,DB01236,Sevoflurane
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],144.4,227642,DB01236,Sevoflurane
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],149.7,227643,DB01236,Sevoflurane
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],57.2,227644,DB01236,Sevoflurane
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],65.3,227645,DB01236,Sevoflurane
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],2.85,227646,DB01236,Sevoflurane
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],3.19,227647,DB01236,Sevoflurane
,30336856,infusion rate,"Mean remifentanil infusion rate [mean (standard deviation)] was significantly higher in the sevoflurane group than in the desflurane group [0.192 (0.064) vs. 0.099 (0.033) μg kg-1 min-1; difference, 0.093 (95% confidence interval, 0.071-0.115); P<0.001].",Desflurane reduces intraoperative remifentanil requirements more than sevoflurane: comparison using surgical pleth index-guided analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336856/),[μg] / [kg·min],0.192,233972,DB01236,Sevoflurane
,30336856,infusion rate,"Mean remifentanil infusion rate [mean (standard deviation)] was significantly higher in the sevoflurane group than in the desflurane group [0.192 (0.064) vs. 0.099 (0.033) μg kg-1 min-1; difference, 0.093 (95% confidence interval, 0.071-0.115); P<0.001].",Desflurane reduces intraoperative remifentanil requirements more than sevoflurane: comparison using surgical pleth index-guided analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336856/),[μg] / [kg·min],0.099,233973,DB01236,Sevoflurane
,15601346,Plasma concentrations,Plasma concentrations [mean +/- sd] of s-ketamine in group IN peaked at 355 +/- 172 ng x ml(-1) within 18 +/- 13 min vs. 1860 +/- 883 ng x ml(-1) within 3 +/- 1 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],355,235889,DB01236,Sevoflurane
,15601346,Plasma concentrations,Plasma concentrations [mean +/- sd] of s-ketamine in group IN peaked at 355 +/- 172 ng x ml(-1) within 18 +/- 13 min vs. 1860 +/- 883 ng x ml(-1) within 3 +/- 1 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],1860,235890,DB01236,Sevoflurane
,15601346,Plasma concentrations,Plasma concentrations of s-norketamine in group IN peaked at 90 +/- 128 ng x ml(-1) within 50 +/- 11 min vs. 429 +/- 277 ng x ml(-1) within 40 +/- 16 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],90,235891,DB01236,Sevoflurane
,15601346,Plasma concentrations,Plasma concentrations of s-norketamine in group IN peaked at 90 +/- 128 ng x ml(-1) within 50 +/- 11 min vs. 429 +/- 277 ng x ml(-1) within 40 +/- 16 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],429,235892,DB01236,Sevoflurane
,15601346,peak plasma concentration,"One child in group IN experienced rapid and high level s-ketamine absorption with a peak plasma concentration of 732 ng x ml(-1) after 2 min, which decreased to 274 ng x ml(-1) after 60 min.",S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],732,235893,DB01236,Sevoflurane
,15601346,peak plasma concentration,"One child in group IN experienced rapid and high level s-ketamine absorption with a peak plasma concentration of 732 ng x ml(-1) after 2 min, which decreased to 274 ng x ml(-1) after 60 min.",S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],274,235894,DB01236,Sevoflurane
,14996264,T95,"The T95 values (+/-sd) for rocuronium were 110.1 +/- 39.3 s and 79.3 +/- 35.6 s for group 1 and group 2, respectively (P < 0.05).",The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),s,110.1,244719,DB01236,Sevoflurane
,14996264,T95,"The T95 values (+/-sd) for rocuronium were 110.1 +/- 39.3 s and 79.3 +/- 35.6 s for group 1 and group 2, respectively (P < 0.05).",The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),s,79.3,244720,DB01236,Sevoflurane
,14996264,T25,The T25 value of group 2 was 40.1 +/- 10.6 min and compared with group 1 values (30.85 +/- 7.02 min) it was significantly longer (P < 0.01).,The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),min,40.1,244721,DB01236,Sevoflurane
,14996264,T25,The T25 value of group 2 was 40.1 +/- 10.6 min and compared with group 1 values (30.85 +/- 7.02 min) it was significantly longer (P < 0.01).,The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),min,30.85,244722,DB01236,Sevoflurane
,16879519,Clearance,"Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml x min(-1) x kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65).",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[ml] / [kg·min],3.91,252905,DB01236,Sevoflurane
,16879519,Clearance,"Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml x min(-1) x kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65).",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[ml] / [kg·min],3.62,252906,DB01236,Sevoflurane
,16879519,Effect compartment concentrations corresponding,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[μg] / [ml],1.41,252907,DB01236,Sevoflurane
,16879519,Effect compartment concentrations corresponding,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[μg] / [ml],2.32,252908,DB01236,Sevoflurane
,16879519,rate constants,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),1/[min],0.10,252909,DB01236,Sevoflurane
,16879519,rate constants,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),1/[min],0.24,252910,DB01236,Sevoflurane
,15502029,time to reach peak concentration,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),h,1.7,257659,DB01236,Sevoflurane
,15502029,peak concentration,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[ng] / [ml],1.83,257660,DB01236,Sevoflurane
,15502029,half-life,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),h,4.7,257661,DB01236,Sevoflurane
,15502029,area under the plasma concentration time curve,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[h] / [ml·ng],6.46,257662,DB01236,Sevoflurane
,15502029,apparent oral volume of distribution (V/F),"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[l] / [kg],17.5,257663,DB01236,Sevoflurane
,15502029,apparent oral clearance (CL/F),"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[l] / [h·kg],3.33,257664,DB01236,Sevoflurane
,27692704,wash-in (,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,0.87,263710,DB01236,Sevoflurane
,27692704,wash-in (,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,1.14,263711,DB01236,Sevoflurane
,27692704,time to reach 50% of arterial steady state) concentration,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,0.87,263712,DB01236,Sevoflurane
,27692704,time to reach 50% of arterial steady state) concentration,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,1.14,263713,DB01236,Sevoflurane
,27692704,terminal half-life,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,10,263714,DB01236,Sevoflurane
,27692704,High-sensitivity troponin concentrations,"High-sensitivity troponin concentrations on the first postoperative morning were 0.355±0.312 µg/mL and 0.225±0.111 µg/mL in the isoflurane and sevoflurane groups, respectively (p = 0.147).","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),[μg] / [ml],0.355,263715,DB01236,Sevoflurane
,27692704,High-sensitivity troponin concentrations,"High-sensitivity troponin concentrations on the first postoperative morning were 0.355±0.312 µg/mL and 0.225±0.111 µg/mL in the isoflurane and sevoflurane groups, respectively (p = 0.147).","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),[μg] / [ml],0.225,263716,DB01236,Sevoflurane
,30117213,half-time,"The equilibration half-time (1.48 minutes) increased with age, but could be predicted using allometry in those under 40 years.",Modeling the pharmacokinetics and pharmacodynamics of sevoflurane using compartment models in children and adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117213/),min,1.48,264246,DB01236,Sevoflurane
